



Hep C Treatment Daklinza Expands Hep C Treatment Options

February 17, 2016 By [Connie M. Welch](#)

Recent new approvals for Hep C treatment bring additional Hep C treatment options for the Hepatitis C virus. Daklinza (daclatasvir) by Bristol Myers-Squibb was approved July 2015 for genotype 3, a once daily pill for use in combination with sofosbuvir, which is used without Interferon. Genotype 3 is the second most common genotype in the United States, with genotype 1 being the most prevalent.

The expanded treatment options for Daklinza include the following:

1. HCV genotype 1 and 3 patients co-infected with HIV-1
2. HCV genotype 1 and 3 post-transplant patients
3. HCV genotype 1 patients with compensated (Child-Pugh A) cirrhosis and decompensated (Child-Pugh B or C) patients
4. HCV genotype 3 patients with decompensated (Child-Pugh B or C) cirrhosis

Additionally, drug to drug interactions data regarding Daklinza coadministered with buprenorphine/naloxone, darunavir/ritonavir, or lopinavir/ritonavir were included in the label.

NS5A resistance testing is recommended for Hep C patients with genotype 1a-with cirrhosis. Screening for the presence of NS5A polymorphisms at amino acid positions M28, Q30, L31, and Y93 is recommended.

Daklinza is a 60 mg oral medication taken once daily, with or without food. Daklinza can be taken with or without Ribavirin depending on liver condition.

Treatment and Duration:

Table 1: Recommended Treatment Regimen and Duration for DAKLINZA in Patients with Genotype 1 or 3 HCV

	Patient Population	Treatment and Duration
Genotype 1	Without cirrhosis	DAKLINZA + sofosbuvir for 12 weeks
	Compensated (Child-Pugh A) cirrhosis	
	Decompensated (Child-Pugh B or C) cirrhosis	DAKLINZA + sofosbuvir + ribavirin for 12 weeks
	Post-transplant	

Table 1: Recommended Treatment Regimen and Duration for DAKLINZA in Patients with Genotype 1 or 3 HCV

	Patient Population	Treatment and Duration
Genotype 3	Without cirrhosis	DAKLINZA + sofosbuvir for 12 weeks
	Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis	DAKLINZA + sofosbuvir + ribavirin for 12 weeks
	Post-transplant	

Dosage Modification Due to Drug Interactions

Refer to the drug interactions and contraindications sections for other drugs before coadministration with DAKLINZA.

Table 2: Recommended DAKLINZA Dosage Modification with CYP3A Inhibitors and Inducers

Concomitant Drugs	DAKLINZA Dosage
Strong CYP3A inhibitors and certain HIV antiviral agents (see Drug Interactions (7.3) for a complete list)	30 mg once daily (one 30 mg tablet)
Moderate CYP3A inducers and nevirapine (see Drug Interactions (7.3) for a complete list)	90 mg once daily (three 30 mg tablets, or one 60 mg and one 30 mg tablet)
Strong CYP3A inducers (see Contraindications (4) for a complete list)	Contraindicated

News of FDA approval to expand treatment options for Daklinza (daclatasvir) by Bristol Myers-Squibb, comes on the heels of recent approval for new Hep C treatment [Zepatier](#), by Merck, for genotype 1 and 4. Another win with expanded treatment options against the Hepatitis C virus.

Daklinza's expanded treatment brings new options to a wide variety of Hep C patients with various degrees of liver damage whom otherwise limited treatment has been available.

The race to bring the cure continues with more Hep C treatment under review by the FDA and predicted to be approved this summer (2016).

Where are you in your journey with Hep C?

This entry was originally published on [Life Beyond Hepatitis C, February 11, 2016](#). It is reprinted with permission.